Abstract: A monoclonal antibody, wherein the monoclonal antibody specifically binds to a single-chain type IV collagen polypeptide, and wherein the monoclonal antibody is obtained by a hybridoma line of Anti NK-Antigen monoclonal antibody #141 having Accession No: FERM BP-11300.

Abstract: Disclosed is a triazole derivative(s) represented by the general formula (1) below or a pharmacologically acceptable salt(s) thereof. Also disclosed are a prodrug(s) of such a triazole derivative(s) and an HSP90 inhibitor(s) containing any one of them as an active constituent. (1) (In the formula, X represents a halogen atom, an optionally substituted alkyl group, an optionally substituted alkynyl group or the like; Y represents a mercapto group, a hydroxyl group, an optionally substituted sulfonyl group, an optionally substituted amino group or the like; and R represents an optionally substituted aryl or alkyl group or the like.

Abstract: A physiologically active substance NK13650P3 having the following physicochemical properties or a pharmacologically acceptable salt thereof. 1) Appearance: pale yellow powder 2) Molecular formula: C29H37N7O15 3) Molecular weight: 723 4) Hydrogen nuclear magnetic resonance spectrum: spectrum measured at 600 MHz in heavy water contains the following signals: chemical shift value ? ppm: 7.05 (1H, 3), 7.00 (1H, d), 6.96 (1H, d), 6.83 (1H, s), etc. 5) Carbon nuclear magnetic resonance spectrum: spectrum measured at 150 MHz in heavy water contains the following signals: chemical shift value ? ppm: 181.5(s), 181.4(s), 179.9(s), 179.2(s), 174.5(s), 174.3(s), 171.5(s), 165.4(s), etc. 6) Ultraviolet light spectrum: spectrum measured in aqueous solution contains the following UV absorption bands: ?max (MeOH): 196.5 nm, 224.5 nm, 322.5 nm 7) Solubility: highly soluble in water but insoluble in methanol, acetone, ethyl acetate, chloroform and dimethyl sulfoxide.

Abstract: The present invention relates to a 3-phenyl-cinnoline compound or a physiologically acceptable salt thereof, and a cell proliferation inhibitor and an antitumor agent comprising the same, as an active ingredient.

Abstract: A physiologically active substance NK13650P3 having the following physicochemical properties or a pharmacologically acceptable salt thereof. 1) Appearance: pale yellow powder 2) Molecular formula: C29H37N7O15 3) Molecular weight: 723 4) Hydrogen nuclear magnetic resonance spectrum: spectrum measured at 600 MHz in heavy water contains the following signals: chemical shift value ? ppm: 7.05(1H, 3), 7.00(1H, d), 6.96(1H, d), 6.83(1H, s), etc. 5) Carbon nuclear magnetic resonance spectrum: spectrum measured at 150 MHz in heavy water contains the following signals: chemical shift value ? ppm: 181.5(s), 181.4(s), 179.9(s), 179.2(s), 174.5(s), 174.3(s), 171.5(s), 165.4(s), etc. 6) Ultraviolet light spectrum: spectrum measured in aqueous solution contains the following UV absorption bands: ?max (MeOH): 196.5 nm, 224.5 nm, 322.5 nm 7) Solubility: highly soluble in water but insoluble in methanol, acetone, ethyl acetate, chloroform and dimethyl sulfoxide.

Abstract: Disclosed is a triazole derivative represented by the general formula (1) below or a pharmacologically acceptable salt thereof. Also disclosed are a prodrug of such a triazole derivative and an HSP90 inhibitor containing any one of them as an active constituent. (1) (In the formula, X represents a halogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group or the like; Y represents a mercapto group, a hydroxyl group, an optionally substituted sulfonyl group, an optionally substituted amino group or the like; and R represents an optionally substituted aryl or amino group or the like.

Abstract: The present invention relates to a 3-phenyl-cinnoline analogue or a physiologically acceptable salt thereof, and a cell proliferation inhibitor and an antitumor agent comprising the same, as an active ingredient.